|
The
drugmaker listed both its assets and liabilities in the range of
$1 million to $10 million in its filing with the U.S. bankruptcy
court for the District of Delaware. (http://1.usa.gov/1mhRYlN)
The move comes on the heels of KaloBios' appeal of the Nasdaq
decision to delist its shares.
A hearing on the appeal has been scheduled for Feb. 25, KaloBios
said on Tuesday.
The company on Monday said two of its directors, Tom Fernandez
and Marek Biestekhad, had resigned in the wake of Shkreli's
arrest for alleged securities fraud.
KaloBios named Shkreli as its CEO on Nov. 20, after Shkreli and
a consortium of investors bought about 70 percent of its shares.
Martin Shkreli gained notoriety when, as the chief executive of
Turing Pharmaceuticals, he raised the price of a drug used to
treat a dangerous parasitic infection to $750 from $13.50. He
resigned as Turing CEO on Dec 18.
Shkreli was arrested on Dec 17 for engaging in what U.S.
prosecutors said was a Ponzi-like scheme at his former hedge
fund and a pharmaceutical company he previously headed.
KaloBios could not be reached immediately for comment outside
regular business hours.
Shares of San Francisco, California-based KaloBios have not
traded since last Thursday.
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
